Rckt stock forecast options market data shows increased

Options market data shows increased call volume on rckt, pushing the stock forecast towards a bullish scenario. This tends to precede moves by institutional buyers, reinforcing the short-term upward bias. D. Boral Capital upgraded Citius Pharmaceuticals (CTXR) to Buy from Hold with a $9 price target. Citius owns 90% of Citius Oncology (CTOR) , which is close to commercializing Lymphir, an immunotherapy for the treatment of adults with relapsed or refractory cutaneous T-cell lymphoma, the firm tells investors in a research note. Multiple analysts have issued price targets for $RCKT recently. We have seen 14 analysts offer price targets for $RCKT in the last 6 months, with a median target of $9.5. Momentum indicators place rckt above its 20-day trendline, boosting the stock forecast outlook. Traders watching MACD convergence see potential for sustained upward swing, especially with volume needing only a 15% boost to trigger institutional alerts.